X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NATCO PHARMA VENUS REMEDIES/
NATCO PHARMA
 
P/E (TTM) x -3.4 13.9 - View Chart
P/BV x 0.1 4.0 3.2% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 VENUS REMEDIES   NATCO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
NATCO PHARMA
Mar-18
VENUS REMEDIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,080 11.7%   
Low Rs61671 9.1%   
Sales per share (Unadj.) Rs301.8592.1 51.0%  
Earnings per share (Unadj.) Rs-24.9188.4 -13.2%  
Cash flow per share (Unadj.) Rs2.5206.3 1.2%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs293.3833.6 35.2%  
Shares outstanding (eoy) m12.3436.90 33.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.31.5 20.9%   
Avg P/E ratio x-3.84.6 -80.9%  
P/CF ratio (eoy) x36.74.2 865.9%  
Price / Book Value ratio x0.31.1 30.3%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m1,15432,311 3.6%   
No. of employees `0000.94.8 19.1%   
Total wages/salary Rs m3933,256 12.1%   
Avg. sales/employee Rs Th4,026.14,522.5 89.0%   
Avg. wages/employee Rs Th425.0674.0 63.1%   
Avg. net profit/employee Rs Th-331.81,439.0 -23.1%   
INCOME DATA
Net Sales Rs m3,72421,848 17.0%  
Other income Rs m23404 5.6%   
Total revenues Rs m3,74722,252 16.8%   
Gross profit Rs m3959,284 4.3%  
Depreciation Rs m338662 51.1%   
Interest Rs m354154 230.1%   
Profit before tax Rs m-2758,872 -3.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,920 1.6%   
Profit after tax Rs m-3076,952 -4.4%  
Gross profit margin %10.642.5 24.9%  
Effective tax rate %-11.521.6 -53.0%   
Net profit margin %-8.231.8 -25.9%  
BALANCE SHEET DATA
Current assets Rs m2,63821,307 12.4%   
Current liabilities Rs m2,3055,920 38.9%   
Net working cap to sales %8.970.4 12.7%  
Current ratio x1.13.6 31.8%  
Inventory Days Days13573 184.9%  
Debtors Days Days46107 43.5%  
Net fixed assets Rs m4,87114,986 32.5%   
Share capital Rs m123369 33.4%   
"Free" reserves Rs m3,49630,353 11.5%   
Net worth Rs m3,61930,760 11.8%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50937,151 20.2%  
Interest coverage x0.258.6 0.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.6 84.3%   
Return on assets %0.619.1 3.3%  
Return on equity %-8.522.6 -37.5%  
Return on capital %1.629.3 5.4%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m010,322 0.0%   
Fx outflow Rs m5172,978 17.3%   
Net fx Rs m-5177,343 -7.0%   
CASH FLOW
From Operations Rs m5144,636 11.1%  
From Investments Rs m-123-11,155 1.1%  
From Financial Activity Rs m-3876,509 -5.9%  
Net Cashflow Rs m4-18 -23.3%  

Share Holding

Indian Promoters % 32.9 52.0 63.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.2 7.8 2.3%  
FIIs % 0.6 16.6 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.0 255.4%  
Shareholders   20,121 25,395 79.2%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 13, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS